Definitive Healthcare Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026. Definitive Healthcare Corp. is a leading provider of healthcare data and analytics, serving approximately 2,260 customers across Life Sciences, Provider, and Diversified markets. The company operates as a single reporting segment, generating revenue primarily through subscription fees for its SaaS platform.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $55.9 million | $59.2 million |
| Gross Profit | $41.7 million | $43.8 million |
| Net Loss (GAAP) | $(192.4) million | $(155.1) million |
| Net Loss Attributable to Company | $(138.6) million | $(107.2) million |
| Adjusted EBITDA | $15.3 million | $14.7 million |
| Cash and Cash Equivalents | $157.6 million | $106.1 million |
| Short-Term Investments | $20.4 million | $17.3 million |
| Term Loan Principal Outstanding | $164.1 million | $166.3 million |
| Revolving Credit Facility Available | $49.7 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6% year-over-year to $55.9 million, driven by a $3.7 million drop in subscription revenue due to sales execution challenges and macroeconomic headwinds. This was partially offset by a $0.5 million increase in professional services.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $197.2 million in Q1 2026, compared to $176.5 million in Q1 2025. This was triggered by sustained declines in market capitalization and stock price.
- Operating Expenses: Total operating expenses increased to $242.9 million (from $228.5 million), primarily due to the goodwill impairment charge. Excluding impairment, core operating expenses decreased due to a restructuring plan reducing headcount by approximately 40 employees.
- Liquidity: Cash and cash equivalents increased to $157.6 million. The company generated $11.6 million in operating cash flow, despite the net loss, largely due to non-cash adjustments (impairment and amortization) and a $13.3 million reduction in accounts receivable.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue to decline in 2026 compared to 2025 due to sales execution challenges, elongated deal cycles, and a shift in customer mix toward single-year subscriptions. Gross margins are also expected to decrease due to revenue declines and the absence of one-time data contract credits received in 2025.
- Restructuring: The "2026 Restructuring Plan" aims to reduce costs and improve margins. Charges of approximately $1.1 million were incurred in Q1, with no further material charges expected for the year.
- Key Risks:
- Macroeconomic Conditions: High interest rates and inflation continue to impact customer spending, particularly in the Life Sciences sector, leading to elevated churn.
- Data Source Disruption: Changes in the healthcare claims data market may negatively impact data acquisition costs.
- Goodwill Impairment: Continued declines in stock price could trigger further impairment charges.
- Legal Proceedings: The company is engaged in litigation regarding contingent consideration for a prior acquisition, though the outcome is not expected to be material.
Investor Verification Checklist
- Verify the sustainability of the Adjusted EBITDA margin (27%) given the projected revenue decline for 2026.
- Monitor the Net Dollar Retention Rate (NDR) and customer churn metrics, specifically within the Life Sciences segment, to assess the impact of macroeconomic headwinds.
- Review the status of the contingent consideration litigation regarding the prior acquisition earn-out.
- Assess the impact of the Tax Receivable Agreement (TRA) liability ($13.0 million) on future cash flows as LLC units are exchanged.
- Confirm the effectiveness of the 2026 Restructuring Plan in stabilizing operating expenses and improving margins in subsequent quarters.